Effects of ions on adenosine binding and enzyme activity of purified S-adenosylhomocysteine hydrolase from bovine kidney

Biochemical Pharmacology

Volumn 56, Issue 11, 1998, Pages 1493-1496

  Kloor, Doris ^a   Fuchs, Sylvia ^a   Petroktistis, Fotios ^a   Delabar, Ursula ^a   Mühlbauer, Bernd ^a   Quast, Ulrich ^a   Osswald, Hartmut ^a  

^a UNIVERSITY OF TÜBINGEN   (Germany)

Author keywords

Apoenzyme; Intracellular adenosine binding; Phosphate; S adenosylhomocysteine hydrolase; Thermodynamic equilibrium

Indexed keywords

ADENOSINE; ADENOSYLHOMOCYSTEINASE; APOENZYME; KIDNEY ENZYME; PHOSPHATE;

ARTICLE; CATTLE; ENZYME ACTIVE SITE; ENZYME ACTIVITY; ENZYME KINETICS; ENZYME PURIFICATION; KIDNEY; NONHUMAN; PRIORITY JOURNAL;

ADENOSINE; ADENOSYLHOMOCYSTEINASE; ANIMALS; BINDING SITES; CALCIUM; CATTLE; CHLORIDES; HYDROLASES; IONS; KIDNEY; KINETICS; MAGNESIUM; PHOSPHATES; POTASSIUM; SODIUM;

EID: 0031738238     PISSN: 00062952     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0006-2952(98)00250-0     Document Type: Article

References (19)

1. de la Haba G., Cantoni G.L. The enzymatic synthesis of S-adenosyl-L-homocysteine from adenosine and homocysteine. J Biol Chem. 234:1959;606-608.
2. Kredich N.M., Hershfield M.S. S-adenosylhomocysteine toxicity in normal and adenosine kinase-deficient lymphoblasts of human origin. Proc Natl Acad Sci USA. 76:1979;2450-2454.
3. Ueland P.M. Pharmacological and biochemical aspects of S-adenosylhomocysteine and S-adenosylhomocysteine hydrolase. Pharmacol Rev. 34:1972;223-253.
4. Ueland P.M., Helland S. Binding of adenosine to intracellular S-adenosylhomocysteine hydrolase in isolated rat hepatocytes. J Biol Chem. 258:1983;747-752.
5. Shatkin A.J. Capping of eucaryotic mRNAs. Cell. 9:1976;645-653.
6. Cools M., Balzarini J., De Clercq E. Mechanism of antiviral and cytotoxic action of (±)-6′ β-fluoroaristeromycin, a potent inhibitor of S-adenosylhomocysteine hydrolase. Mol Pharmacol. 39:1991;718-724.
7. Liu S., Wnuk S.F., Yuan C., Robins M.J., Borchardt R.T. Adenosine-5′-carboxaldehyde A potent inhibitor of S-adenosyl-L-homocysteine hydrolase . J Med Chem. 36:1993;883-887.
8. Osswald H. Topical composition for treating herpes with adenosine. USP 5034382. 1991.
9. Hershfield M.S., Kredich N.M. S-adenosylhomocysteine hydrolase is an adenosine binding protein A target for adenosine toxicity . Science. 202:1978;757-760.
10. Palmer J.L., Abeles R.H. The mechanism of action of S-adenosylhomocysteinase. J Biol Chem. 254:1978;1217-1225.
11. Kloor D., Fuchs S., Kurz J., Faust B., Osswald H. S-adenosylhomocysteine-hydrolase from bovine kidney Enzymatic and binding properties . Kidney and Blood Pressure Res. 19:1996;100-108.
12. Gomi T., Takata Y., Fujioka M. Rat liver S-adenosylhomocysteinase. Spectrophotometric study of coenzyme binding. Biochim Biophys Acta. 994:1989;172-179.
13. Matuszewska B., Borchardt R.T. The role of nicotineamide adenine dinucleotide in the inhibition of bovine liver S-adenosylhomocysteine hydrolase by neplanocin A. J Biol Chem. 262:1987;265-268.
14. Fujioka M., Takata Y. S-adenosylhomocysteine hydrolase from rat liver. Purification and some properties. J Biol Chem. 256:1981;1631-1635.
15. Freeman D., Bartlett S., Radda G., Russ B. Energetics of sodium transport in the kidney. Saturation transfer 31P-NMR. Biochem Biophys Acta. 762:1983;325-336.
16. Kloor D., Stumvoll W., Faust B., Delabar D., Mühlbauer B., Osswald H. Does S-adenosyl-homocysteine (SAH) accumulate in the ischemic rat kidney? Naunyn-Schmiedeberg's Arch Pharmacol. 353:1996;R11.
17. Osswald H., Schmitz H.J., Kemper R. Tissue content of adenosine, inosine and hypoxanthine in the rat kidney after ischemia and postischemic recirculation. Pflügers Arch. 371:1977;45-49.
18. De Clercq E. S-Adenosylhomocysteine hydrolase inhibitors as broad-spectrum antiviral agents. Biochem Pharmacol. 36:1987;2567-2575.
19. Daelemans D., Este J.A., Witvrouw M., Pannecouque C., Jonckheere H., Aquaro S., Perno C.F., De Clercq E., Vandamme A.M. S-adenosylhomocysteine hydrolase inhibitors interfere with the replication of human immunodeficiency virus type 1 through inhibition of the LTR transactivation. Mol Pharmacol. 52:1997;1157-1163.